Research
Hormonal
GLP-1 receptor agonists and SGLT2 inhibitors show promising benefits for NAFLD/NASH patients, particularly by addressing underlying metabolic dysfunction, though specific histological resolution data is still emerging.
If lifestyle changes aren't enough to manage your fatty liver, ask your doctor about GLP-1 agonists (like semaglutide) or SGLT2 inhibitors (like empagliflozin). These diabetes/obesity drugs have shown promise in improving liver health by targeting the underlying metabolic issues.
GoodSupportsHIGH confidence
Therapeutic approaches originally envisaged for type 2 diabetes or obesity (such as glucagon-like peptide-1 receptor agonists, sodium-glucose co-transporter-2 inhibitors, insulin sensitizers and bariatric surgery) have shown promising signs of benefit for patients with NAFLD/NASH.
Why this rating
Based on a literature review of recent trials.
Source
<scp>Nonalcoholic fatty liver disease</scp> as a metabolic disease in humans: A literature review
Bertrand Cariou et al. · Diabetes Obesity and Metabolism · 2021
DOI 10.1111/dom.14322
narrative_reviewCited 167×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weight loss of 7-10% is required to resolve NAFLD, but achieving this through lifestyle changes alone is difficult as only 10-20% of individuals succeed, and weight loss is less effective for NASH resolution in diabetic patients.Good
- Lean individuals can develop NAFLD due to visceral adiposity and insulin resistance, and this condition carries similar risks of fibrosis and NASH as obesity-related NAFLD.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →